Immuron (IMRN) Competitors

Immuron logo
$0.90 +0.05 (+5.86%)
Closing price 11/20/2026 03:49 PM Eastern
Extended Trading
$0.83 -0.07 (-7.54%)
As of 11/20/2026 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IMRN vs. MGX, ACET, NXTC, BYSI, and EVAX

Should you buy Immuron stock or one of its competitors? Immuron's main competitors and comparable companies include Metagenomi (MGX), Adicet Bio (ACET), NextCure (NXTC), BeyondSpring (BYSI), and Evaxion A/S (EVAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immuron compare to Metagenomi?

Immuron (NASDAQ:IMRN) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

In the previous week, Immuron had 1 more articles in the media than Metagenomi. MarketBeat recorded 1 mentions for Immuron and 0 mentions for Metagenomi. Immuron's average media sentiment score of 0.00 equaled Metagenomi'saverage media sentiment score.

Company Overall Sentiment
Immuron Neutral
Metagenomi Neutral

Immuron has higher revenue and earnings than Metagenomi.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immuron$7.71M0.94-$2.50MN/AN/A
Metagenomi$7.09M3.05-$87.87M-$2.50N/A

Immuron has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

0.1% of Immuron shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Comparatively, 12.5% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Metagenomi has a consensus price target of $6.00, suggesting a potential upside of 950.79%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Immuron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuron
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Metagenomi
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Immuron has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Immuron's return on equity of 0.00% beat Metagenomi's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuronN/A N/A N/A
Metagenomi -384.61%-75.04%-50.29%

Summary

Immuron beats Metagenomi on 8 of the 13 factors compared between the two stocks.

How does Immuron compare to Adicet Bio?

Immuron (NASDAQ:IMRN) and Adicet Bio (NASDAQ:ACET) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Adicet Bio has a consensus price target of $37.80, suggesting a potential upside of 1,666.36%. Given Adicet Bio's stronger consensus rating and higher probable upside, analysts plainly believe Adicet Bio is more favorable than Immuron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuron
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Adicet Bio
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

Immuron's return on equity of 0.00% beat Adicet Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuronN/A N/A N/A
Adicet Bio N/A -69.71%-56.97%

Immuron has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Adicet Bio has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

0.1% of Immuron shares are owned by institutional investors. Comparatively, 83.9% of Adicet Bio shares are owned by institutional investors. 7.0% of Immuron shares are owned by company insiders. Comparatively, 3.4% of Adicet Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Immuron has higher revenue and earnings than Adicet Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immuron$7.71M0.94-$2.50MN/AN/A
Adicet BioN/AN/A-$116.80M-$8.57N/A

In the previous week, Immuron had 1 more articles in the media than Adicet Bio. MarketBeat recorded 1 mentions for Immuron and 0 mentions for Adicet Bio. Immuron's average media sentiment score of 0.00 equaled Adicet Bio'saverage media sentiment score.

Company Overall Sentiment
Immuron Neutral
Adicet Bio Neutral

Summary

Immuron and Adicet Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does Immuron compare to NextCure?

NextCure (NASDAQ:NXTC) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

NextCure currently has a consensus price target of $20.00, suggesting a potential upside of 210.08%. Given NextCure's stronger consensus rating and higher probable upside, analysts plainly believe NextCure is more favorable than Immuron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NextCure
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Immuron
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

42.7% of NextCure shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 11.9% of NextCure shares are owned by insiders. Comparatively, 7.0% of Immuron shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Immuron's return on equity of 0.00% beat NextCure's return on equity.

Company Net Margins Return on Equity Return on Assets
NextCureN/A -191.33% -125.95%
Immuron N/A N/A N/A

NextCure has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Immuron has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

In the previous week, NextCure had 1 more articles in the media than Immuron. MarketBeat recorded 2 mentions for NextCure and 1 mentions for Immuron. NextCure's average media sentiment score of 0.67 beat Immuron's score of 0.00 indicating that NextCure is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NextCure
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immuron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immuron has higher revenue and earnings than NextCure.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCureN/AN/A-$55.84M-$6.77N/A
Immuron$7.71M0.94-$2.50MN/AN/A

Summary

NextCure beats Immuron on 8 of the 12 factors compared between the two stocks.

How does Immuron compare to BeyondSpring?

Immuron (NASDAQ:IMRN) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

0.1% of Immuron shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 7.0% of Immuron shares are held by company insiders. Comparatively, 29.3% of BeyondSpring shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BeyondSpring has lower revenue, but higher earnings than Immuron.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immuron$7.71M0.94-$2.50MN/AN/A
BeyondSpring$1.75M7.81-$1.01M-$0.12N/A

In the previous week, BeyondSpring had 1 more articles in the media than Immuron. MarketBeat recorded 2 mentions for BeyondSpring and 1 mentions for Immuron. BeyondSpring's average media sentiment score of 0.44 beat Immuron's score of 0.00 indicating that BeyondSpring is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immuron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BeyondSpring
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immuron has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, BeyondSpring has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
ImmuronN/A N/A N/A
BeyondSpring N/A N/A -43.12%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuron
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BeyondSpring
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

BeyondSpring beats Immuron on 6 of the 9 factors compared between the two stocks.

How does Immuron compare to Evaxion A/S?

Immuron (NASDAQ:IMRN) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

0.1% of Immuron shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 7.0% of Immuron shares are held by insiders. Comparatively, 41.6% of Evaxion A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Evaxion A/S had 7 more articles in the media than Immuron. MarketBeat recorded 8 mentions for Evaxion A/S and 1 mentions for Immuron. Immuron's average media sentiment score of 0.00 beat Evaxion A/S's score of -0.36 indicating that Immuron is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immuron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Evaxion A/S
0 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immuron has higher revenue and earnings than Evaxion A/S.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immuron$7.71M0.94-$2.50MN/AN/A
Evaxion A/S$7.49M2.71-$7.71M-$2.44N/A

Immuron's return on equity of 0.00% beat Evaxion A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuronN/A N/A N/A
Evaxion A/S N/A -126.83%-70.63%

Evaxion A/S has a consensus target price of $11.25, indicating a potential upside of 400.00%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than Immuron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuron
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Evaxion A/S
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Immuron has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Summary

Evaxion A/S beats Immuron on 7 of the 13 factors compared between the two stocks.

Get Immuron News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMRN vs. The Competition

MetricImmuronBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$7.26M$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.62%
P/E RatioN/A23.0732.5628.68
Price / Sales0.9414.927.725.17
Price / CashN/A21.9220.2520.77
Price / Book0.964.124.343.51
Net Income-$2.50M-$24.08M$3.51B$394.12M
7 Day Performance2.80%-9.85%-8.07%-8.97%
1 Month Performance-5.21%-12.77%-10.29%-11.61%
1 Year Performance-45.96%-7.99%-4.70%-11.21%

Immuron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMRN
Immuron
0.6076 of 5 stars
$0.90
+5.9%
N/A-46.0%$7.26M$7.71MN/A7
MGX
Metagenomi
2.2648 of 5 stars
$0.76
+8.0%
$6.00
+693.3%
-62.2%$28.57M$25.21MN/A113
ACET
Adicet Bio
3.4438 of 5 stars
$2.99
-0.3%
$37.80
+1,164.2%
-77.8%$27.99MN/AN/A102
NXTC
NextCure
3.1098 of 5 stars
$5.98
flat
$20.00
+234.4%
-38.6%$27.39MN/AN/A40
BYSI
BeyondSpring
0.3267 of 5 stars
$0.64
+11.1%
N/A-82.8%$26.47MN/AN/A44

Related Companies and Tools


This page (NASDAQ:IMRN) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners